HSBC downgraded Shanghai Fosun to Hold from Buy with a price target of HK$20, down from HK$40. The analyst cut estimates for 2023 due to the high base in 2022 with large COVID-19-related revenue and continued uncertainties such as Gland Pharma’s recovery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>